Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Hand-Held Image-Guided Percutaneous Access Device Precisely Targets Anatomical Structures

By HospiMedica International staff writers
Posted on 12 Jun 2023

Early central venous catheter (CVC) insertion has been shown to significantly decrease mortality and hospitalization rates in severely ill patients in the ICU and ER. More...

Now, a groundbreaking handheld device that combines imaging and robotics aims to enhance the precision, safety, and reliability of accessing targeted anatomical structures. This advanced technology, designed specifically for high-volume procedures such as CVC placement, could help healthcare professionals of different training levels and experience to safely and effectively achieve vascular access.

Obvius Robotics (Weston, FL, USA) has developed CERTA Access System, an innovative technology platform for performing percutaneous access. This system integrates image guidance and accurate needle placement in a handheld device, which enables clinicians to swiftly and reliably identify target structures like blood vessels, and obtain access for procedures such as CVC placement in the subclavian and jugular veins.

Currently in the development stage, the CERTA Access System allows clinicians to target and access anatomical structures single-handedly at the push of a button, using a unique targeting system and needle assembly. While the CERTA Access System has successfully completed its first study in humans, it is not yet commercially available, as the company is in the process of seeking regulatory approval and preparing for market launch.

"CERTA enables clinicians of various levels of experience to quickly and reliably treat these patients, and in so doing, democratizes and standardizes a common procedure that today requires a certain level of skill and experience," said William Cohn, MD, Chief Medical Officer of Obvius Robotics and inventor of the CERTA Access System.

"This successful first-in-human study comes after two years of rigorous work proving the design and value proposition in a preclinical setting," added Russell Seiber, CEO and President of Obvius Robotics. "We hope this will mark an important milestone in bringing this potentially groundbreaking technology to patients on a global scale."

Related Links:
Obvius Robotics


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: A smartphone application displays a glucose concentration that was measured using the new sensor (Photo courtesy of Chuchu Chen and Yonghao Fu)

Wearable Device for Diabetics Could Replace Continuous Glucose Monitoring Systems

Monitoring blood glucose is essential for people with diabetes to prevent complications and maintain long-term health. Current continuous glucose monitoring systems require needles inserted under the skin,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.